Filed Pursuant to Rule 424(b)(5)
Registration No. 333-237989
PROSPECTUS SUPPLEMENT
(To Prospectus dated May 12, 2020)
SHARPLINK GAMING LTD.
1,413,075 Ordinary Shares
Pre-Funded Warrants to Purchase 1,253,592 Ordinary Shares
Pursuant to this prospectus supplement and the accompanying prospectus (the “accompanying prospectus”), we are offering to Alpha Capital Anstalt (“Alpha”) 1,413,075 ordinary shares, par value NIS 0.06 per share, at an offering price of $3.75 per share, and pre-funded warrants to purchase 1,253,592 ordinary shares at an exercise price of $0.01 per ordinary share (the “Pre-Funded Warrants”), for a purchase price of $3.74 per Pre-Funded Warrant. In addition, concurrently with the offering of ordinary shares and pre-funded warrants, but not pursuant to this prospectus supplement or the accompanying prospectus, we are offering to Alpha warrants to purchase 2,666,667 ordinary shares at an exercise price of $4.50 per ordinary share (the “Private Warrants”). The Private Warrants are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), are not being offered pursuant to this prospectus supplement and the accompanying prospectus, and are being sold pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.
Our ordinary shares are listed on The NASDAQ Capital Market under the symbol “SBET.” On November 16 2021, the last reported sale price of our ordinary shares on The NASDAQ Capital Market was $4.07 per share.
As of November 16, 2021, the aggregate market value of our ordinary shares held by non-affiliates pursuant to General Instruction I.B.5 to Form F-3 was $57,334,476 which was calculated based on 11,132,908 outstanding ordinary shares held by non-affiliates and at a price of $3.70 per share, the closing sale price of our ordinary shares reported on The Nasdaq Capital Market on November 12, 2021. As a result, we are eligible to offer and sell up to an aggregate of $13,730,572 of our ordinary shares pursuant to General Instruction I.B.5. of Form F-3. Following this offering, we will have sold securities with an aggregate market value of $10,000,000 pursuant to General Instruction I.B.5. of Form F-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement.
As of the date of this prospectus supplement, an aggregate of $10,000,000 of ordinary shares and other securities remain unsold under the registration statement on Form F-3 (File No. 333-237989) we filed with the Securities and Exchange Commission on May 4, 2020 and declared effective on May 12, 2020.
Investing in our securities involves substantial risks. See “RISK FACTORS” beginning on page S-5 of this prospectus. You should carefully read this prospectus and the documents incorporated herein before making any investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Public Offering Price | ||||
Per Ordinary Share | $ | 3.75 | ||
Total for Ordinary Shares | $ | 5,299,031 | ||
Per Pre-Funded Warrants | $ | 3.74 | ||
Total for Pre-Funded Warrants | $ | 4,688,434 | ||
Proceeds to us, before expenses | $ | 9,987,465 |
The date of this prospectus supplement is November 16, 2021.
TABLE OF CONTENTS
Page | |
PROSPECTUS SUPPLEMENT | |
About This Prospectus Supplement | S-ii |
Cautionary Note Regarding Forward-Looking Statements | S-ii |
Summary | S-1 |
The Offering | S-2 |
Risk Factors | S-3 |
Use of Proceeds | S-5 |
Dividend Policy | S-5 |
Dilution | S-6 |
Description of the Securities We Are Offering | S-7 |
Plan of Distribution | S-8 |
Private Placement Transaction | S-8 |
Legal Matters | S-9 |
Experts | S-9 |
Where You Can Find More Information | S-9 |
Information Incorporated By Reference | S-10 |
PROSPECTUS | |
3
|
|
3
|
|
16
|
|
16
|
|
17
|
|
17
|
|
20
|
|
23
|
|
24
|
|
24
|
|
25
|
|
25
|
|
25
|
|
25
|
|
25
|
|
26
|
|
26
|
|
26
|
|
26
|
S-i
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first is this prospectus supplement, which contains specific information about the terms of this offering. The second is the accompanying prospectus, which provides you with general information, some of which may not apply to this offering. This prospectus supplement also adds to, updates and changes information contained in the accompanying prospectus. If there is any inconsistency between the information in this prospectus supplement and the accompanying prospectus, you should rely on this prospectus supplement. Before purchasing any securities, you should carefully read both this prospectus supplement and the accompanying prospectus, together with the additional information described under the headings “Where You Can Find More Information” and “Incorporation of certain Information by Reference.”
References in this prospectus to “Old SharpLink” refer to SharpLink, Inc., a Minnesota corporation, which we acquired in a reverse merger completed on July 26, 2021, pursuant to that certain Agreement and Plan of Merger among us, Old SharpLink and New SL Acquisition Corp. dated April 15, 2021, or the Merger Agreement. References in this prospectus to the “Company,” “we,” “us” and “our” refer to SharpLink Gaming Ltd., an Israeli company formerly known as Mer Telemanagement Solutions Ltd.
On July 26, 2021, we completed a 1-for-2 reverse stock split, which we refer to in this prospectus as the Reverse Stock Split. Unless otherwise noted herein, references to shares of capital stock in this prospectus give effect to this Reverse Stock Split.
Both of our and Old SharpLink’s financial statements are prepared and presented in accordance with accounting principles generally accepted in the U.S., or GAAP. Neither our nor Old SharpLink’s historical results necessarily indicate our expected results for any future periods.
We have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus supplement, any document incorporated by reference, the accompanying prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell the shares in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement and the accompanying prospectus or any free writing prospectus is accurate as of the date on its respective cover, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and the accompanying prospectus, including information set forth or incorporated by reference into this prospectus supplement and accompanying prospectus, contains statements that constitute forward-looking information statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our plans, and objectives and expectations for future operations, and in statements containing words such as “believes,” “estimates,” “anticipates,” “intends,” “continues,” “contemplates,” “expects,” “may,” “will,” “could,” “should,” or “would” or other similar words or phrases. These statements, which are based on information currently available to us, are not guarantees and involve risks and uncertainties that could cause actual results to materially differ from those expressed in, or implied by, these statements, including those described under “Risk Factors” and in the Company’s filings with the SEC that are incorporated herein by reference. Readers should not place undue reliance on forward-looking statements. These forward-looking statements speak only as of the date on which the statements were made and we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statement included in this prospectus or elsewhere, except as required by law.
S-ii
This summary highlights information contained elsewhere in this prospectus supplement and the accompanying prospectus. Because it is a summary, it may not contain all of the information that is important to you. Accordingly, before making an investment decision, you are urged to carefully review this prospectus supplement and the accompanying prospectus in its entirety, including the risks of investing in our securities discussed under the caption “Risk Factors” and the financial statements and other information that is contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus supplement and the accompanying prospectus is a part.
Company Overview
We are a business-to-business, or B2B, provider of advanced technology that seamlessly connects sports fans with online sports betting bookmakers, which we refer to as our Affiliate Marketing Services, and a leading U.S. provider of free to play games and betting feed integrations, which we refer to as our Sports Gaming Client Services.
We recently completed a merger between New SL Acquisition Corp., our wholly-owned subsidiary, and Old SharpLink. We acquired our Affiliate Marketing Services and Sports Gaming Client Services businesses as a result of the merger, and following the merger, we changed our name from Mer Telemanagement Solutions Ltd. to SharpLink Gaming Ltd and our ticker symbol from MTSL to SBET. We also continue to operate our legacy business, which provides solutions for telecommunications expense management, or TEM, including enterprise mobility management software, usage and accounting software, and contact center software. We refer to this business as our Legacy Business.
Our Affiliate Marketing Services business focuses on acquiring sports fans through our partnerships with professional sports leagues, large sports media websites and our own network of related sports websites, bringing them highly relevant and timely sports betting content. Specifically, our analytical software tools allow us to collect data on sports fans, intelligently connect those fans with personally relevant sports betting offers, and convert the sports fans into paying customers for online bookmakers. Our vision is to be the leader in the emerging U.S. sports gaming and betting markets by developing advanced technology that seamlessly connects sports fans with online sports bookmakers.
Our Sports Gaming Client Services business has been providing custom development, hosting and management services for free-to-play games and prize-winning contests for major sports leagues and media companies for over 15 years. In addition to our traditional games development business, we have developed and deployed betting integration services for major leagues in the U.S. By leveraging our technology and building on our current client relationships, we believe we are well positioned to earn a leadership position in the rapidly evolving sports betting industry by delivering high-value users to gaming operators.
Our Legacy Business provides TEM solutions that allow enterprises and organizations to make smarter choices with their telecommunications spending at each stage of the service lifecycle, including allocation of cost, proactive budget control, fraud detection, processing of payments and spending forecasting. More information about our Legacy Business can be found in our Annual Report on Form 20-F for the year ended December 31, 2020, filed with the Securities and Exchange Commission, or SEC, on May 17, 2021, which is incorporated by reference herein.
Our management team has more than 100 years of combined experience delivering innovative sports solutions to partners such as Turner Sports, Google, Facebook, the National Football League (NFL), the National Collegiate Athletic Association (NCAA) and the National Basketball Association (NBA), among many other iconic organizations, with executive experience at companies such as ESPN, NBC, Sportradar, AOL, Cantor Gaming, Betfair and others. Our current Sports Gaming Client Services business was originally established in 2006 as Sports Technologies Inc., or STI, which was founded by our Chief Operating Officer. STI was acquired by SportsHub Games Network, Inc., or SportsHub, one of our significant shareholders in 2016. In November 2020, SportsHub spun-off and we subsequently acquired STI in an all-stock transaction.
We were incorporated under the laws of the State of Israel in December 1995. We are a public limited liability company under the Israeli Companies Law 1999-5759, or the Israeli Companies Law, and operate under this law and associated legislation. Our registered offices is located at 14 Hatidhar Street, P.O. Box 2112, Ra΄anana 4366516, Israel, our principal place of business is located at 333 Washington Ave. N, Suite 104, Minneapolis, MN 55401, USA, and our telephone number is (612) 293-0619. Our website address is www.sharplink.com. The information on our website is not incorporated by reference into this prospectus.
Reverse Merger with Old SharpLink
On July 26, 2021, we completed a merger of New SL Acquisition Corp., our wholly-owned subsidiary formed under the laws of the State of Delaware, and Old SharpLink, a company incorporated under the laws of the State of Minnesota, pursuant to an Agreement and Plan of Merger we entered into on April 15, 2021. As set forth in the Merger Agreement, New SL Acquisition Corp. merged with and into Old SharpLink with Old SharpLink remaining as the surviving corporation and our wholly-owned subsidiary. We refer to this merger and related transactions as the Merger, and references to the Company mean the combined company following the Merger.
Immediately following the closing of the Merger, the former Old SharpLink securityholders immediately before the Merger owned approximately 86% of the Ordinary Shares of the Company, on a fully-diluted, as-converted basis. Such percentage included a stock option pool equal to 10% of the Ordinary Shares of the Company, on a fully-diluted, as-converted basis, immediately following the Closing. In connection with the Merger, the directors and officers of the Company were replaced with directors and officers of and nominated by Old SharpLink.
S-1
The Offering |
Purchaser: | Alpha Capital Anstalt (“Alpha”) | |
Ordinary shares offered by us: | 1,413,075 shares | |
Pre-Funded Warrants offered by us: | 1,253,592 | |
Ordinary shares outstanding before this offering (1): | 20,316,775 shares (as more fully described in the notes following this table) | |
Ordinary shares outstanding after completion of this offering (1): | 21,729,850 shares (assuming none of the Pre-Funded Warrants issued in this offering or the Private Warrants issued in the concurrent private placement are exercised) | |
Manner of offering | Registered direct offering. See “Plan of Distribution” on page S-10 of this prospectus supplement. | |
Description of Pre-Funded Warrants: | Each Pre-Funded Warrant will have an exercise price of $0.01 per share, will be exercisable upon issuance and will expire only when exercised in full. | |
Concurrent private placement | In a concurrent private placement, we are selling to Alpha warrants to purchase 2,666,667 ordinary shares at a price of $4.50 per share (the “Private Warrants”). The Private Warrants are exercisable six months following issuance and terminate four years following issuance. The Private Warrants and the ordinary shares issuable upon exercise of such Private Warrants are not being registered under the Securities Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. See “Private Placement Transaction.” |
Use of Proceeds: |
We estimate that our net proceeds from this offering will be approximately $9.9 million, excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants or the Private Warrants. We intend to use the net proceeds from this offering to support our technology and business development initiatives, as well as for general working capital purposes.
See the section titled “Use of Proceeds” in this prospectus supplement. | |
NASDAQ Capital Market symbol: | SBET | |
Trading: | Our shares of ordinary shares currently trade on NASDAQ. We do not plan on applying to list the Pre-Funded Warrants or the Private Warrants on NASDAQ, any national securities exchange or any other nationally recognized trading system. The Pre-Funded Warrants and the Private Warrants will not be transferrable except pursuant to their terms. | |
Risk Factors: | Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See “Risk Factors” below and in our most recent Annual Report on Form 20-F, which is incorporated by reference and the other information included elsewhere in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider before deciding to invest in our ordinary shares or warrants to purchase our ordinary shares. |
_____________
(1) | The number of shares of our ordinary shares shown above to be outstanding immediately before and after this offering is based on 20,316,775 ordinary shares outstanding as of November 16, 2021, and excludes, as of such date: |
● | 1,797,824 ordinary shares subject to outstanding options having a weighted average exercise price of $4.85 per share; | |
● | 1,236,552 ordinary shares reserved for future issuance pursuant to our existing stock incentive plans; | |
● | 93,333 ordinary shares subject to outstanding warrants having a weighted average exercise price of $1.85 per share; and | |
● | 54,737 ordinary shares issuable upon conversion of Series A-1 Preferred Shares and 124,810 ordinary shares issuable upon conversion of Series B Preferred Shares. |
S-2
In addition to the other information included in this prospectus, you should carefully consider the following risk factors before determining to purchase the ordinary shares or Pre-funded Warrants offered hereby. The following is not intended to be an exhaustive list of the risks related to the Company, the Transaction or our business. You should also read and consider the risk factors described under (i) Part 1, Item 3, “Key Information – Risk Factors” of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on May 17, 2021, and (ii) the section captioned “Risk Factors” in the Company’s proxy statement filed as Exhibit 99.2 to its Report on Form 6-K filed with the SEC on June 16, 2021, which annual report and proxy statement are incorporated herein by reference.
Risks Related to this Offering
The market price of our ordinary shares has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation.
The trading price for our ordinary shares has been, and we expect it to continue to be, volatile. The price at which our ordinary shares trade depends upon a number of factors, including our historical and anticipated operating results, our financial situation, announcements of technological innovations or new products by us or our competitors, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions. Some of these factors are beyond our control. Broad market fluctuations may lower the market price of our ordinary shares and affect the volume of trading in our stock, regardless of our financial condition, results of operations, business or prospect.
Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.
We intend to use the net proceeds from this offering primarily to continue funding the development of our technology, for business development, and for working capital purposes. In addition, we may use the proceeds of this offering for the acquisition of other businesses, technology, or assets, although we have not entered into any agreements related to acquisitions. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds we will have upon completion of the offering. Accordingly, we will retain broad discretion over the use of these proceeds.
You will experience immediate and substantial dilution as a result of this offering and may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants.
Since the public offering price our ordinary shares and Pre-Funded Warrants will be substantially higher than the net tangible book value per share of our ordinary shares, you will suffer substantial dilution in the net tangible book value of the ordinary shares and the ordinary shares underlying the Pre-Funded Warrants you purchase in this offering. Our pro-forma net tangible book value as of December 31, 2020, after giving effect to the merger of SharpLink, Inc. and Mer Telemanagement Solutions Ltd. (“MTS”), our predecessor, and the proceeds of the offering of ordinary shares and Pre-Funded Warrants in the offering, was approximately $0.71 per share. As a result, if you purchase ordinary shares at the offer price of $3.75 per share (including through the purchase and exercise of a Pre-Funded Warrant, you will suffer immediate and substantial dilution of $3.04 per share in the net tangible book value of the ordinary shares you acquire. See the section titled “Dilution” below for a more detailed discussion of the dilution you would incur if you purchase ordinary shares or Pre-Funded Warrants.
In order to raise additional capital or pursue strategic transactions, we may in the future offer, issue or sell additional ordinary shares or other securities convertible into or exchangeable for our ordinary shares, including the issuance of ordinary shares in relation to the achievement of milestones. Our stockholders may experience significant dilution as a result of future equity offerings or issuances. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders.
S-3
Future sales of our ordinary shares in the public market could cause our stock price to fall.
Sales of a substantial number of ordinary shares in the public market, or the perception that these sales might occur, could depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. As of November 16, 2021, we had 20,316,775 ordinary shares outstanding, all of which, other than shares held by our directors, certain officers, and certain shareholders, were eligible for sale in the public market. In addition, all of the shares of ordinary shares issuable upon exercise of warrants will be freely tradable without restriction or further registration upon issuance.
Holders of our warrants will have no rights as shareholder until they acquire our ordinary shares.
Until you acquire ordinary shares upon exercise of your Pre-Funded Warrants, you will have no rights as a shareholder. Upon exercise of your Pre-Funded Warrants, you will be entitled to exercise the rights of a shareholder only as to matters for which the record date occurs after the exercise date.
A large number of shares issued in this offering may be sold in the market following this offering, which may depress the market price of our ordinary shares.
A large number of shares issued in this offering may be sold in the market following this offering, which may depress the market price of our ordinary shares. Sales of a substantial number of ordinary shares in the public market following this offering could cause the market price of our ordinary shares to decline. If there are more ordinary shares offered for sale than buyers are willing to purchase, then the market price of our ordinary shares may decline to a market price at which buyers are willing to purchase the offered shares of our ordinary shares and sellers remain willing to sell the shares. All of the securities issued in the offering will be freely tradable without restriction or further registration under the Securities Act.
There is currently no public market for the Pre-Funded Warrants or the Private Warrants being offered in this offering and in the concurrent private placement, and the terms of the Pre-Funded Warrants and the Private Warrants prevent free trading of such warrants.
We do not plan on applying to list the Pre-Funded Warrants or the Private Warrants on NASDAQ, any national securities exchange or any other nationally recognized trading system. Moreover, the terms of the Pre-Funded Warrants or the Private Warrants prevent free trading of such warrants.
S-4
We intend to use the net proceeds from this offering primarily to continue funding the development of our technology, for business development, and for working capital purposes. In addition, we may use the proceeds of this offering for the acquisition of other businesses, technology, or assets, although we have not entered into any agreements related to acquisitions.
After deducting the placement agent fee and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $9.9 million. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering, if any. As a result, our management will have broad discretion regarding the timing and application of the net proceeds from this offering.
We have never declared or paid any cash dividends on our ordinary shares and do not currently anticipate declaring or paying cash dividends on our ordinary shares in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance operations. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future prospects, contractual restrictions and other factors that our board of directors may deem relevant.
S-5
If you purchase our ordinary shares in this offering, you will experience dilution to the extent of the difference between the amount per share paid by purchasers of ordinary shares in this offering and our as adjusted net tangible book value per share immediately after this offering. Net tangible book value per share is equal to the amount of our total tangible assets (totals assets excluding intangible assets and goodwill), less total liabilities, divided by the aggregate number of outstanding ordinary shares, Series A-1 Preferred Shares and Series B Preferred Shares; with each of the Series convertible into one ordinary share.
Our net tangible book value as of December 31, 2020, which represents the pre-merger financial position of SharpLink, Inc. and Mer Telemanagement Solutions Ltd. (“MTS”), our predecessor, and pro forma adjustments described Exhibit 99.2 to our Form 6-K filed on June 16, 2021, giving effect to the acquisition of SharpLink, Inc. by MTS as if such acquisition had been completed on December 31, 2020, was $6,610,000, or $0.32 per ordinary share (including the ordinary shares issuable upon conversion of the preferred B shares). Net tangible book value represents the amount of our total tangible assets less our total liabilities.
Our pro forma net tangible book value as of December 31, 2020,, after giving effect to our receipt of an estimated $9,900,000 in net proceeds from the issuance and sale of 1,413,075 ordinary shares and the prefunded warrants to purchase up to 1,253,592 ordinary shares, was $16,510,000, or $0.71 per ordinary share. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of common and convertible preferred series shares outstanding as of December 31, 2020, after giving effect to the pro forma adjustment described above.
The following table illustrates this dilution:
Public offering price per share | $ | 3.75 | ||||||
Net tangible book value per share as of December 31, 2020 | $ | 0.32 | ||||||
Increase in net tangible book value per share attributable to pro forma adjustment described above | $ | 0.39 | ||||||
Pro forma net tangible book per share as of December 31, 2020 | $ | 0.71 | ||||||
Net dilution per share to investors in this offering | $ | 3.04 |
The number of shares of our ordinary shares utilized above to be outstanding immediately before and after this offering is based on 20,316,775 ordinary shares outstanding as of November 16, 2021, 54,737 ordinary shares issuable upon conversion of Series A-1 Preferred Shares and 124,810 ordinary shares issuable upon conversion of Series B Preferred Shares and excludes, as of such date:
● | 1,797,824 ordinary shares subject to outstanding options having a weighted average exercise price of $4.85 per share; | |
● | 1,236,552 ordinary shares reserved for future issuance pursuant to our existing stock incentive plans; and | |
● | 93,333 ordinary shares subject to outstanding warrants having a weighted average exercise price of $1.85 per share. |
In addition, we may choose to raise additional capital depending on market conditions, our capital requirements, and strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.
S-6
DESCRIPTION OF THE SECURITIES WE ARE OFFERING
Ordinary Shares
We are offering 1,413,075 ordinary shares, par value NIS 0.06 per share, to Alpha Capital Anstalt at an offering price of $3.75 per share. The material terms and provisions of our ordinary shares are described under the heading “Description of Share Capital” starting on page 20 of the accompanying prospectus.
Pre-Funded Warrants
We are offering pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,253,592 of our ordinary shares. Each Pre-Funded Warrant has an exercise price of $0.01 per share. The Pre-Funded Warrants will be exercisable upon issuance and will expire only when exercised in full. The exercise of the Pre-Funded Warrants is subject to certain exercise limitations, such that the holder may not exercise the Pre-Funded Warrants if such exercise results in the holder becoming the beneficial owner of more than 9.99% of the number of ordinary shares outstanding immediately after giving effect to such exercise, provided that, upon prior notice to us, the holder may increase or decrease such limitation up to a maximum of 9.99% of the number of ordinary shares outstanding, provided that any increase in such beneficial ownership shall not be effective until 61 days following such notice. The Pre-Funded Warrants will have a cashless exercise right.
The Pre-Funded Warrants provide for the adjustment of the exercise price and number of shares issuable upon exercise of the Pre-Funded Warrants in connection with stock dividends and splits, such that the number of shares issuable upon exercise of the Pre-Funded Warrants is adjusted in proportion to the change in the number of shares outstanding and the aggregate exercise price of the Pre-Funded Warrants remains unchanged. In addition, if we grant, issue or sell any ordinary share equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of shares (and not the holder of the Pre-Funded Warrants), then the Pre-Funded Warrant holder will be entitled to acquire, upon the terms applicable to such purchase rights, the aggregate purchase rights which the holder could have acquired if the holder had held the number of ordinary shares acquirable upon complete exercise of the Pre-Funded Warrants. If we declare or make any dividend or other distribution of our assets to holders of our ordinary shares, the Pre-Funded Warrant holder shall be entitled to participate in the distribution to the same extent that the holder would have participated therein if the holder had held the number of ordinary shares acquirable upon complete exercise of the Pre-Funded Warrants. Other than as described above, the Pre-Funded Warrants do not contain anti-dilution provisions.
Upon the reclassification, reorganization or recapitalization of our ordinary shares, or merger or consolidation with or into another entity, the consummation of a stock purchase agreement whereby more than 50% of our outstanding ordinary shares are acquired by another person or entity, or a sale or other disposition of substantially all of our assets, the holder of each of the Pre-Funded Warrants is entitled to receive, upon exercise of such warrant, the number of our ordinary shares or the number of ordinary shares of our successor or acquirer that such holder would have been entitled to receive immediately prior to such transaction, and the exercise price for such shares shall be adjusted based on the amount of any alternate consideration receivable as a result of such transaction by a holder of the number of ordinary shares for which the Pre-Funded Warrants is exercisable immediately prior to such transaction.
The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice. No fractional ordinary shares will be issued in connection with the exercise of a Pre-Funded Warrant. Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent. We do not plan on applying to list the Pre-Funded Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder’s ownership of our ordinary shares, the holder of Pre-Funded Warrants does not have the rights or privileges of a holder of our ordinary shares, including any voting rights, until the holder exercises the Pre-Funded Warrant. Amendments and waivers of the terms of the Pre-Funded Warrants require the written consent of the holder of such Pre-Funded Warrant and us.
S-7
We are offering our ordinary shares and our Pre-Funded Warrants directly to the purchaser pursuant to this prospectus supplement and the accompanying prospectus. We have not engaged an agent or other finder to assist us in connection with this offering,
We will enter into a securities purchase agreement directly with the purchaser of the ordinary shares and the Pre-Funded Warrants offered by this prospectus supplement, and we will only sell to the purchasers who have entered into such agreement. The form of the securities purchase agreement will be included as an exhibit to a report on Form 6-K that we will file with the SEC and that will be incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus forms a part.
We will deliver the shares being issued to the purchaser electronically upon receipt of the purchaser’s funds for the ordinary shares being purchased pursuant to this prospectus supplement. We will deliver the Pre-Funded Warrants by delivery of an executed agreement. We expect to deliver the ordinary shares and the Pre-Funded Warrants being offering pursuant to this prospectus supplement on or about November 19, 2021, which will be deemed the closing date.
The estimated offering expenses payable by us are approximately $100,000, which includes legal, accounting and printing costs, as well as fees and expenses payable to the transfer agent of our ordinary shares. After deducting these expenses, we expect the net proceeds from this offering to be approximately $9.9 million.
In a concurrent private placement (the “private placement transaction”), we are selling to the purchaser, for each ordinary share and each Pre-Funded Warrant purchased in this offering, a warrant to purchase one ordinary share (the “Private Warrants”). The Private Warrants are initially exercisable six months following issuance and terminate four years following issuance. The Private Warrants have an exercise price of $4.50 per share and are exercisable to purchase an aggregate of 2,666,667 ordinary shares. Neither the Private Warrants nor the ordinary shares issuable upon exercise of the Private Warrants are being registered under the Securities Act, nor are they being offered pursuant to this prospectus supplement and the accompanying prospectus. The Private Warrants and the ordinary shares issuable upon their exercise are being sold pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.
The following is a brief summary of the Private Warrants and is subject to, and qualified in its entirety by, the terms set forth in the forms of the Private Warrants to be filed as an exhibit to our report on Form 6-K, which we expect to file with the Securities and Exchange Commission in connection with this offering and the private placement transaction.
The Private Warrants will be exercisable six months following the date of issuance and will expire on the fourth anniversary of the date of issuance. The exercise of the Private Warrants is subject to certain exercise limitations, such that the holder may not exercise the Private Warrants if such exercise results in the holder becoming the beneficial owner of more than 9.99% of the number of ordinary shares outstanding immediately after giving effect to such exercise, provided that, upon prior notice to us, the holder may increase or decrease such limitation up to a maximum of 9.99% of the number of ordinary shares outstanding, provided that any increase in such beneficial ownership shall not be effective until 61 days following such notice. If at the time of exercise of the Private Warrants there is not then a current and effective registration statement covering the resale of the ordinary shares issuable upon exercise of the Private Warrants, then the holder of the Warrants may exercise on a cashless (net) exercise basis.
The Private Warrants provide for the adjustment of the exercise price and number of shares issuable upon exercise of the Private Warrants in connection with stock dividends and splits, such that the number of shares issuable upon exercise of the Private Warrants is adjusted in proportion to the change in the number of shares outstanding and the aggregate exercise price of the Private Warrants remains unchanged. In addition, if we grant, issue or sell any ordinary share equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of shares (and not the holder of the Private Warrants), then the Private Warrant holder will be entitled to acquire, upon the terms applicable to such purchase rights, the aggregate purchase rights which the holder could have acquired if the holder had held the number of ordinary shares acquirable upon complete exercise of the Private Warrants. If we declare or make any dividend or other distribution of our assets to holders of our ordinary shares, the Private Warrant holder shall be entitled to participate in the distribution to the same extent that the holder would have participated therein if the holder had held the number of ordinary shares acquirable upon complete exercise of the Private Warrants. Other than as described above, the Private Warrants do not contain anti-dilution provisions.
S-8
Upon the reclassification, reorganization or recapitalization of our ordinary shares, our merger or consolidation with or into another entity, the consummation of a stock purchase agreement whereby more than 50% of our outstanding ordinary shares are acquired by another person or entity, or a sale or other disposition of substantially all of our assets, the holder of each of the Private Warrants is entitled to receive, upon exercise of such warrant, the number of our ordinary shares or the number of ordinary shares of our successor or acquirer that such holder would have been entitled to receive immediately prior to such transaction, and the exercise price for such shares shall be adjusted based on the amount of any alternate consideration receivable as a result of such transaction by a holder of the number of ordinary shares for which the Private Warrants is exercisable immediately prior to such transaction.
The Private Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice. No fractional ordinary shares will be issued in connection with the exercise of a Private Warrant. Subject to applicable laws, the Private Warrants may be offered for sale, sold, transferred or assigned without our consent. The Private Warrants will not be listed on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. Except as otherwise provided in the Private Warrants or by virtue of such holder’s ownership of our ordinary shares, the holder of Private Warrants does not have the rights or privileges of a holder of our ordinary shares, including any voting rights, until the holder exercises the Private Warrant. Amendments and waivers of the terms of the Private Warrants require the written consent of the holder of such Private Warrant and us.
The validity of the securities being offered by this prospectus and other legal matters concerning this offering relating to Israeli law will be passed upon for us by Ephraim Abramson & Co., Law Offices, Tel Aviv, Israel. Fredrikson & Byron, P.A., Minneapolis, Minnesota, will be passing upon matters of United States law for us with respect to securities offered by this prospectus supplement.
The consolidated financial statements incorporated in this prospectus by reference from our Annual Report on Form 20-F for the year ended December 31, 2020 have been audited by Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global, Independent Registered Public Accounting Firm as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about our ability to continue as a going concern as described in Note 1 to the consolidated financial statements) incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
The consolidated financial statements of for SharpLink, Inc. and subsidiary as of December 31, 2020 and 2019, and for each of the years in the two-year period ended December 31, 2020 incorporated in this prospectus by reference from the Proxy Statement of the Company filed as Exhibit 99.2 to the Company’s Report on Form 6-K filed with the SEC on June 16, 2021 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon incorporated herein by reference, and have been incorporated into this prospectus supplement and the registration statement on Form F-3 of which this prospectus supplement is a part in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus supplement regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov.
S-9
We also maintain a website at www.sharplink.com, through which you can access our SEC filings. The information set forth on, or accessible from, our website is not part of this prospectus.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” the information we have filed with it, which means that we can disclose important information to you by referring you to another document that we have filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this prospectus. Any statement in a document we incorporated by reference into the accompanying prospectus or this prospectus supplement will be considered to be modified or superseded to the extent a statement contained in this prospectus or any other subsequently filed document that is incorporated by reference into this prospectus modifies or supersedes that statement. The modified or superseded statement will not be considered to be a part of this prospectus, except as modified or superseded.
We incorporate by reference the following information or documents that we have filed with the SEC (excluding those portions of any document that are “furnished” and not “filed” in accordance with SEC rules):
● | our Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on May 17, 2021; | |
● | our Reports on Form 6-K filed on each of April 15, 2021, May 17, 2021, May 24, 2021, June 16, 2021, July 22, 2021, July 27, 2021, July 28, 2021, August 17, 2021, September 30, 2021, and November 10, 2021; | |
● | Any future reports on Form 6-K filed after the date of this prospectus supplement to the extent that we indicate they are incorporated by reference into this registration statement; | |
● | Any future annual reports on Form 20-F that we may file with the SEC under the Exchange Act, prior to the termination of any offering contemplated by the prospectus; and | |
● | The description of our ordinary shares contained in our Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on May 17, 2021 under the Exchange Act and any amendment or report filed for the purpose of updating that description. |
Certain statements in and portions of this prospectus update and replace information in the above listed documents incorporated by reference. Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements in and portions of this prospectus or the above listed documents.
We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all the information that has been incorporated by reference in this prospectus but not delivered with this prospectus (and any exhibits specifically incorporated in such information), at no cost, upon written or oral request to us at the following address:
SharpLink Gaming Ltd.,
333 Washington Avenue North, Suite 104
Minneapolis, MN 55401
Attn: Brian Bennett, Chief Financial Officer
Telephone: (612) 293-0619
Copies of these filings are also available, without charge, on our website at www.sharplink.com as soon as reasonably practicable after they are filed electronically with the SEC. You may also obtain additional information about us by visiting our website. The information contained on our website is not a part of this prospectus.
S-10
3
|
|
3
|
|
16
|
|
16
|
|
17
|
|
17
|
|
20
|
|
23
|
|
24
|
|
24
|
|
25
|
|
25
|
|
25
|
|
25
|
|
25
|
|
26
|
|
26
|
|
26
|
|
26
|
• |
demand for our products;
|
• |
ability to retain existing customers;
|
• |
changes in our pricing policies or those of our competitors;
|
• |
new product announcements by us and our competitors;
|
• |
the number, timing and significance of product enhancements;
|
• |
product life cycles;
|
• |
our ability to develop, introduce and market new and enhanced products on a timely basis;
|
• |
changes in the level of our operating expenses;
|
• |
budgeting cycles of our customers;
|
• |
customer order deferrals in anticipation of enhancements or new products that we or our competitors offer;
|
• |
changes in our strategy;
|
• |
seasonal trends and general domestic and international economic and political conditions, among others; and
|
• |
currency exchange rate fluctuations and economic conditions in the geographic areas where we operate.
|
• |
the impact of recessionary environments in multiple foreign markets;
|
• |
costs of localizing products for foreign markets;
|
• |
foreign currency exchange rate fluctuations
|
• |
longer receivables collection periods and greater difficulty in accounts receivable collection;
|
• |
unexpected changes in regulatory requirements;
|
• |
difficulties and costs of staffing and managing foreign operations;
|
• |
reduced protection for intellectual property rights in some countries;
|
• |
potentially adverse tax consequences; and
|
• |
political and economic instability.
|
• |
quarterly variations in our operating results;
|
• |
operating results that vary from the expectations of securities analysts and investors;
|
• |
changes in expectations as to our future financial performance, including financial estimates by investors;
|
• |
announcements of technological innovations or new products by us or our competitors;
|
• |
announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;
|
• |
announcements by third parties of significant claims or proceedings against us;
|
• |
changes in the status of our intellectual property rights;
|
• |
additions or departures of key personnel;
|
• |
future sales of our ordinary shares; and
|
• |
general stock market prices and volume fluctuations.
|
|
●
|
to or through one or more underwriters on a firm commitment or best efforts basis;
|
|
|
|
|
●
|
to or through dealers, who may act as agents or principals, including a block trade (which may involve crosses) in which a broker or dealer so engaged will attempt to sell as agent but may
position and resell a portion of the block as principal to facilitate the transaction;
|
|
|
|
|
●
|
through agents;
|
|
|
|
|
●
|
through privately negotiated transactions;
|
|
|
|
|
●
|
directly to purchasers, including our affiliates;
|
|
|
|
|
●
|
purchases by a broker or dealer as principal and resale by such broker or dealer for its own account pursuant to this prospectus;
|
|
|
|
|
●
|
exchange distributions and/or secondary distributions;
|
|
|
|
|
●
|
ordinary brokerage transactions and transactions in which the broker solicits purchasers;
|
|
|
|
|
●
|
to one or more underwriters for resale to the public or to investors;
|
|
|
|
|
●
|
in “at the market offerings,” to or through a market maker or into an existing trading market, on an exchange or otherwise;
|
|
|
|
|
●
|
transactions not involving market makers or established trading markets, including direct sales or privately negotiated transactions;
|
|
|
|
|
●
|
transactions in options, swaps or other derivatives that may or may not be listed on an exchange; or
|
|
|
|
|
●
|
in any combination of these methods of sale.
|
|
●
|
the name or names and addresses of any underwriters, dealers or agents;
|
|
|
|
|
●
|
the purchase price of the securities and the proceeds to us from the sale;
|
|
|
|
|
●
|
any underwriting discounts and commissions or agency fees and other items constituting underwriters’ or agents’ compensation;
|
|
●
|
the public offering price;
|
|
|
|
|
●
|
any discounts or concessions allowed or reallowed or paid to dealers;
|
|
|
|
|
●
|
any securities exchanges or markets on which such securities may be listed; and
|
|
|
|
|
●
|
any delayed delivery arrangements.
|
• |
equal rights to receive an invitation to, attend all of and vote at all of the general meetings of the company. Each one of the ordinary shares will confer upon the holder a single vote at
every general meeting of the company at which he/she participates and votes, by himself/herself, by agent, or by proxy.
|
• |
equal rights to receive dividends, if and when distributed, whether in cash or any other manner, and to participate in a distribution of bonus shares, if and when distributed, according to
the ratio between the shareholders’ holdings in the company’s issued and outstanding share capital (ordinary shares and preferred shares on an as-converted basis, without regard to the Beneficial Ownership Limitation (as explained
below)) and the company’s total issued and outstanding share capital (ordinary shares and preferred shares on an as-converted basis, without regard to the Beneficial Ownership Limitation).
|
• |
equal right to participate in a distribution of the company’s assets available for distribution, in the event of liquidation or winding-up of the company, pari-passu with the preferred
shares (on an as-converted basis).
|
• |
equal rights to receive dividends, if and when distributed, whether in cash or any other manner, and to participate in a distribution of bonus shares, if and when distributed, according to
the ratio between the shareholders’ holdings in the company’s issued and outstanding share capital (ordinary shares and preferred shares on an as-converted basis, without regard to the Beneficial Ownership Limitation) and the company’s
total issued and outstanding share capital (ordinary shares and preferred shares on an as-converted basis, without regard to the Beneficial Ownership Limitation).
|
• |
equal right to participate in a distribution of the company’s assets available for distribution, in the event of liquidation or winding-up of the company, on an as-converted basis,
pari-passu with the ordinary shares.
|
• |
a right of conversion into ordinary shares. Each preferred share shall be convertible, at any time and from time to time at the option of
the shareholder thereof, into such amount of ordinary shares determined by dividing the Per Preferred Share Purchase Price (as defined in our Articles, currently $1.14, subject to adjustments) by the conversion price then in effect, or
the Conversion Rate. The initial Conversion Rate is 1:1. As to Alpha Capital Anstalt, from the closing date of the Securities Purchase Agreement between us and Alpha Capital Anstalt, dated September 6, 2018, or the Alpha SPA, and until
36 months from the closing date, if and whenever we issue or sell ordinary hares or ordinary shares equivalents (as such term is defined in Alpha SPA) for a consideration per share that is less than the conversion price then in effect,
or the Discounted Per Ordinary Share Purchase Price, and which is not an Exempted Issuance (as such term is defined in the Alpha SPA), then immediately after such dilutive issuance, the conversion price shall be reduced to equal the
Discounted Per Ordinary Share Purchase Price, but in no event shall the conversion price become lower than the greater of (i) $US 0.10 or (ii) 20% of the closing price on the trading day immediately prior to the date of the Alpha SPA.
|
• |
equal rights to vote on all matters submitted to a vote of the ordinary shares (on an as-converted basis, but only up to the number of votes equal to the number of ordinary shares into
which the preferred shares would be convertible pursuant to the Beneficial Ownership Limitation on the record date for any such vote).
|
• |
Any amendment, alteration or repeal of any provision of the Articles so as to adversely affect the special rights, preferences, privileges or voting powers of the Preferred Shares, subject
to certain exceptions.
|
• |
Any consummation of a binding share exchange or reclassification involving the Preferred Shares, or of a merger or consolidation of the company with or into another entity, subject to
certain exceptions.
|
|
●
|
the specific designation and aggregate number of, and the price at which we will issue, the warrants;
|
|
|
|
|
●
|
the currency or currency units in which the offering price, if any, and the exercise price are payable;
|
|
|
|
|
●
|
the designation, amount, and terms of the securities purchasable upon exercise of the warrants;
|
|
|
|
|
●
|
if applicable, the exercise price for ordinary shares and the number of ordinary shares to be received upon exercise of the warrants;
|
|
|
|
|
●
|
if applicable, the exercise price for our debt securities, the amount of debt securities to be received upon exercise, and a description of that series of debt securities;
|
|
|
|
|
●
|
the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period,
the specific date or dates on which you may exercise the warrants;
|
|
|
|
|
●
|
whether the warrants will be issued in fully registered form or bearer form, in definitive or global form, or in any combination of these forms, although, in any case, the form of a warrant
included in a unit will correspond to the form of the unit and of any security included in that unit;
|
|
|
|
|
●
|
any applicable material U.S. federal income tax consequences;
|
|
|
|
|
●
|
the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars, or other agents;
|
|
|
|
|
●
|
the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange;
|
|
|
|
|
●
|
if applicable, the date from and after which the warrants and the ordinary shares and/or debt securities will be separately transferable;
|
|
|
|
|
●
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at any other time;
|
|
|
|
|
●
|
information with respect to book-entry procedures, if any;
|
|
|
|
|
●
|
the anti-dilution provisions of the warrants, if any;
|
|
|
|
|
●
|
any redemption or call provisions;
|
|
|
|
|
●
|
whether the warrants are to be sold separately or with other securities as parts of units; and
|
|
|
|
|
●
|
any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants.
|
|
●
|
the price, if any, for the subscription rights;
|
|
|
|
|
●
|
the exercise price payable for each ordinary share upon the exercise of the subscription rights;
|
|
|
|
|
●
|
the number of subscription rights to be issued to each shareholder;
|
|
|
|
|
●
|
the number and terms of the shares ordinary shares which may be purchased per each subscription right;
|
|
|
|
|
●
|
the extent to which the subscription rights are transferable;
|
|
|
|
|
●
|
any other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of the subscription rights;
|
|
|
|
|
●
|
the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire;
|
|
|
|
|
●
|
the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities; and
|
|
|
|
|
●
|
if applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by us in connection with the offering of subscription rights.
|
|
●
|
the material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;
|
|
|
|
|
●
|
any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and
|
|
|
|
|
●
|
any material provisions of the governing unit agreement that differ from those described above.
|
SEC Registration Fee
|
$
|
1,298
|
||
Legal fees and expenses
|
12,500
|
|||
Accountants’ fees and expenses
|
4,500
|
|||
Miscellaneous
|
5,000
|
|||
Total
|
$
|
23,298
|
|
●
|
Our 2019 Form 20-F, filed with the SEC on March 26, 2020;
|
|
|
|
● |
Our Form 6-K filed with the SEC on May 4, 2020;
|
|
|
●
|
Any future reports on Form 6-K to the extent that we indicate they are incorporated by reference into this registration statement;
|
|
|
|
|
●
|
Any future annual reports on Form 20-F that we may file with the SEC under the Exchange Act, prior to the termination of any offering contemplated by the prospectus; and
|
|
|
|
|
●
|
The description of our ordinary shares contained in our Annual Report on Form 20-F for the year ended December 31, 2019, filed with the SEC on March 26, 2020 under the Exchange Act and any
amendment or report filed for the purpose of updating that description.
|
27
MER Telemanagement Solutions Ltd.
Ordinary Shares
Warrants
Subscription Rights
Units
PROSPECTUS
You should rely only on the information incorporated by reference or provided in this prospectus and in any accompanying prospectus supplement. We have not authorized anyone to provide you with different information. We are not making any offer to sell or buy any of the securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date that appears below. |
||